Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Imugene ( (AU:IMU) ) has issued an update.
Imugene Limited has announced the cessation of a small tranche of its convertible notes, with 25 IMUAAR convertible securities cancelled by mutual agreement between the company and the noteholder on 18 December 2025. The move marginally simplifies Imugene’s capital structure and slightly reduces its outstanding convertible debt, though the limited size of the cancellation suggests a modest immediate impact on the company’s overall financing position.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an ASX-listed biotechnology company focused on developing novel immuno-oncology therapies, with its securities traded under the issuer code IMU on the Australian Securities Exchange.
YTD Price Performance: -75.76%
Average Trading Volume: 1,891,756
Technical Sentiment Signal: Sell
Current Market Cap: A$96.19M
For an in-depth examination of IMU stock, go to TipRanks’ Overview page.